Quarterly Result30 Jul 2026, 02:40 pm
Ajanta Pharma Declares ₹32/Share Interim Dividend, Q1 PAT Up 31%
AI Summary
Ajanta Pharma Ltd. announced its unaudited consolidated and standalone financial results for the first quarter ended June 30, 2026. The company reported a 25% increase in revenue to ₹1,626 crore and a 31% rise in Profit After Tax (PAT) to ₹334 crore compared to the same period last year. The Board of Directors also approved a first interim dividend of ₹32 per share for FY 2027, amounting to ₹400 crore, with a record date set for August 5, 2026. Key growth drivers included a 57% surge in US Generic revenue and strong performance in India branded generics, exceeding IPM growth.
Key Highlights
- Q1 FY27 consolidated revenue grew 25% YoY to ₹1,626 crore.
- Q1 FY27 PAT increased 31% YoY to ₹334 crore.
- Approved interim dividend of ₹32 per share, totaling ₹400 crore.
- US Generic revenue surged 57% in the quarter.
- ROCE at 37% and RONW at 28%.
Price Impact
More from AJANTPHARM